The Dry (Atrophic) Macular Degeneration drugs in development market research report provides comprehensive information on the therapeutics under development for Dry (Atrophic) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Dry (Atrophic) Macular Degeneration. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Dry (Atrophic) Macular Degeneration and features dormant and discontinued products.
GlobalData tracks 93 drugs in development for Dry (Atrophic) Macular Degeneration by 82 companies/universities/institutes. The top development phase for Dry (Atrophic) Macular Degeneration is preclinical with 56 drugs in that stage. The Dry (Atrophic) Macular Degeneration pipeline has 88 drugs in development by companies and four by universities/ institutes. Some of the companies in the Dry (Atrophic) Macular Degeneration pipeline products market are: MD Healthcare, Kira Pharmaceuticals and Astellas Pharma.
The key targets in the Dry (Atrophic) Macular Degeneration pipeline products market include Complement C3 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 1 or C3), Peroxisome Proliferator Activated Receptor Alpha (Nuclear Receptor Subfamily 1 Group C Member 1 or NR1C1 or PPARA), and Peroxisome Proliferator Activated Receptor Gamma (Nuclear Receptor Subfamily 1 Group C Member 3 or NR1C3 or PPARG).
The key mechanisms of action in the Dry (Atrophic) Macular Degeneration pipeline product include Complement C3 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 1 or C3) Inhibitor with three drugs in Preclinical. The Dry (Atrophic) Macular Degeneration pipeline products include nine routes of administration with the top ROA being Intravitreal and 14 key molecule types in the Dry (Atrophic) Macular Degeneration pipeline products market including Small Molecule, and Gene Therapy.
Dry (Atrophic) Macular Degeneration overview
Dry (atrophic) macular degeneration is a common eye disorder affecting the macula, the central part of the retina responsible for sharp, central vision. It’s characterized by the gradual deterioration of light-sensitive cells in the macula. Symptoms include blurred central vision, difficulty seeing fine details, and in later stages, the presence of drusen (yellow deposits) in the retina. Dry AMD typically progresses slowly and may affect one or both eyes. While there’s no outright cure, certain lifestyle changes like a healthy diet, quitting smoking, protecting eyes from UV light, and regular eye exams can help slow its progression. In some cases, specific vitamin supplements may also be recommended. Monitoring and early detection are crucial to manage the condition and prevent severe vision loss.
For a complete picture of Dry (Atrophic) Macular Degeneration’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
